[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.128.52. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 227
Citations 0
Comment & Response
January 2015

Criteria for Waiver of Informed Consent for Quality Improvement Research—Reply

Author Affiliations
  • 1Department of Epidemiology and Biostatistics, University of California, San Francisco
  • 2Department of Medicine, University of California, San Francisco
  • 3Clinical and Translational Science Institute, University of California, San Francisco
  • 4The Greenwall Foundation, New York, New York
  • 5Deputy Editor, JAMA Internal Medicine
JAMA Intern Med. 2015;175(1):143. doi:10.1001/jamainternmed.2014.6997

In Reply We thank Baker and Persell for their thoughtful response. It is indeed useful to consider specific criteria for deciding when a waiver of consent is justified, and we generally agree with the criteria they propose. We also wish to emphasize their and our recommendation that an institutional review board be involved in decision making. The decision to waive consent in a randomized clinical trial is an important one that should be vetted carefully by a disinterested panel, even if the study can be considered a “quality improvement” project.

First Page Preview View Large
First page PDF preview
First page PDF preview
×